BiomX (PHGE) Stock Price, News & Analysis

Company Overview

BiomX Inc. is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis. Preclinical studies have demonstrated the ability of BiomX’s phage preparations to reduce targeted bacterial populations implicated in inflammation and disease progression. Advanced product characterization and manufacturing processes support both oral and topical delivery formats, positioning BiomX to advance multiple candidates through regulatory pathways.

Founded in 2016 as a spin-out from MIGAL – Galilee Research Institute, BiomX is headquartered in Rehovot, Israel, with a U.S. presence in Cambridge, Massachusetts. The company conducts clinical trials across North America and Europe, collaborating with academic medical centers and contract research organizations. Since its initial public listing on the NYSE American exchange under the ticker PHGE, BiomX has expanded its leadership team to include executives with deep expertise in phage biology, clinical development and biomanufacturing. The company’s research and development efforts are overseen by CEO Eliora Ron, who guides strategic initiatives to translate microbiome science into targeted, next-generation therapies.

Key Stats

• Today's Range: $0.68 to $0.76
• 50-Day Range: $0.63 to $7.50
• 52-Week Range: $0.62 to $14.71
• Volume: 340,238 shs
• Average Volume: 441,876 shs
• Market Capitalization: $1.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.00
• Consensus Rating: Hold

BiomX Stock Analysis - MarketRank™

BiomX scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

BiomX has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

BiomX has a consensus price target of $26.00, representing about 3,723.5% upside from its current price of $0.68.

Amount of Analyst Coverage

BiomX has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for BiomX are expected to decrease in the coming year, from ($5.85) to ($6.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BiomX is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BiomX is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.27% of the float of BiomX has been sold short.

Short Interest Ratio / Days to Cover

BiomX has a short interest ratio ("days to cover") of 0.58, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BiomX has recently decreased by 9.08%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BiomX does not currently pay a dividend.

Dividend Growth

BiomX does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: N/A

News Sentiment

BiomX has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for BiomX this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for PHGE on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added BiomX to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BiomX insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,900,000.00 in company stock.

Percentage Held by Insiders

21.80% of the stock of BiomX is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PHGE Stock Analysis - Frequently Asked Questions

How have PHGE shares performed this year?

BiomX's stock was trading at $1.87 at the beginning of the year. Since then, PHGE stock has decreased by 63.6% and is now trading at $0.68.

How were BiomX's earnings last quarter?

BiomX Inc. (NYSEAMERICAN:PHGE) posted its quarterly earnings results on Thursday, February, 19th. The company reported $6.99 earnings per share for the quarter.

When did BiomX's stock split?

BiomX's stock reverse split on Tuesday, November 25th 2025.The 1-19 reverse split was announced on Friday, November 14th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of BiomX?

Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BiomX own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BiomX investors own include Moderna (MRNA), T2 Biosystems (TTOO), Chegg (CHGG), Aldeyra Therapeutics (ALDX), Nokia (NOK), Avino Silver & Gold Mines (ASM) and Anavex Life Sciences (AVXL).

Company Calendar

• Last Earnings: 2/19/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:PHGE
• Previous Symbol: NYSEMKT:PHGE
• CIK: 1739174
• Web: www.biomx.com
• Phone: 972-7-2394-2377
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BiomX: $26.00
• High Price Target: $26.00
• Low Price Target: $26.00
• Potential Upside/Downside: +3,723.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -2,923.50%
• Return on Assets: -83.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.87
• Quick Ratio: 0.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($12.50) per share
• Price / Book: -0.05

Miscellaneous

• Outstanding Shares: 1,590,000
• Free Float: 1,247,000
• Market Cap: $1.08 million
• Optionable: N/A
• Beta: 1.02